Table 1.
Demographic characteristics of included atopic dermatitis patients and their disease severity at baseline and after upadacitinib treatment
| Patient No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Demographic characteristics | |||||||
| Gender | F | F | F | F | M | M | M |
| Age (y/o) | 20 | 30 | 25 | 22 | 32 | 34 | 30 |
| IgE (IU/mL) | 1508 | 334 | 57.1 | 1526 | 17508 | 1931 | 228 |
| Weight (kg) | 61 | 67 | 49 | 52 | 78 | 77 | 69 |
| Previous treatment | MTX | MTX | UVB | UVB | Systemic CS | UVB | Systemic CS |
| Disease severity | |||||||
| Baseline EASI | 19.8 | 18.2 | 14.1 | 16.1 | 17.4 | 11.3 | 19.4 |
| Baseline ADCT | 14 | 17 | 16 | 8 | 10 | 11 | 21 |
| Response to Upa | |||||||
| EASI Post 2 months 30mg/day (ΔEASI)a | 1.9 (90.4) | 1.8 (90.1) | 0.4 (97.2) | 1.4 (91.3) | 9.9 (43.1) | 0 (100) | 1.9 (90.2) |
| EASI Post 2 months 15mg/day (ΔEASI) | 2.0 (89.9) | 2.5 (86.3) | 0.4 (97.2) | 2.6 (83.9) | 8.9b (48.9) | 0 (100) | 2.8 (85.5) |
| Dosing reduction | Y | Y | Y | Y | N | Y | Y |
| ADCT Post 2 months 30mg/day | 1 | 4 | 0 | 2 | 10 | 0 | 9 |
| ADCT Post 2 months 15mg/day | 3 | 7 | 2 | 3 | 8b | 0 | 8 |
| Discontinuation of UPA | |||||||
| EASI score c | 2.65 | 9.8 | 0.8 | 2.6 | 14.7 | 0 | 12.0 |
| ADCT score c | 13 | 13 | 10 | 1 | 16 | 0 | 22 |
| Treatment required | MTX | MTX+UVB | AZA | AnH | CsA | AnH | Upa + UVB |
a
ΔEASI: Percentage change in EASI score as compared with baseline EASI.
b
response to additional 1 month of 30mg/day treatment due to not achieving EASI-90.
c
within 1 month (before restart of systemic treatment for AD).
ADCT = Atopic Dermatitis Control Tool; AnH = Antihistamine; AZA = azathioprine; CS = corticosteroids; CsA = cyclosporine; EASI = Eczema Area and Severity Index; MTX = methotrexate; Upa = upadacitinib; UVB = narrow-band UVB.